ArticleBMC bioinformatics2020
In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform.
Article in BMC bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 0 citations in OpenAlex.
- Structural homology and binding ability comparisons of epitope pair candidates for molecular mimicry triggering of type 1 diabetes mellitus.Oxford open immunology · 2026Article
- Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis.PLoS computational biology · 2026Article
- Immunoinformatics-based design of a next generation multi-epitope vaccine candidate against Shigella boydii using a hierarchical subtractive proteomics approach.Scientific reports · 2025Article
- An open source statistical web application for validation and analysis of virtual cohorts.Scientific reports · 2025Article
- An overview of immunotoxicity in drug discovery and development.Toxicology letters · 2025Review
- A systematic review of cardiacProgress in biomedical engineering (Bristol, England) · 2023Review
- Beyond the state of the art of reverse vaccinology: predicting vaccine efficacy with the universal immune system simulator for influenza.BMC bioinformatics · 2023Article
- In Silico Studies to Support Vaccine Development.Pharmaceutics · 2023Review
- Chimeric vaccine design against the conserved TonB-dependent receptor-like β-barrel domain from the outer membrane tbpA and hpuB proteins ofFrontiers in molecular biosciences · 2023Article
- Computational identification of differentially-expressed genes as suggested novel COVID-19 biomarkers: A bioinformatics analysis of expression profiles.Computational and structural biotechnology journal · 2023Article
- Comprehensive Highlights of the Universal Efforts towards the Development of COVID-19 Vaccine.Vaccines · 2022Review
- The Promises of Speeding Up: Changes in Requirements for Animal Studies and Alternatives during COVID-19 Vaccine Approval-A Case Study.Animals : an open access journal from MDPI · 2022Article
- Model verification tools: a computational framework for verification assessment of mechanistic agent-based models.BMC bioinformatics · 2022Article
- Model Integration in Computational Biology: The Role of Reproducibility, Credibility and Utility.Frontiers in systems biology · 2022Article
- Translatability and transferability of in silico models: Context of use switching to predict the effects of environmental chemicals on the immune system.Computational and structural biotechnology journal · 2022Article
- Computational modelling and simulation for immunotoxicity prediction induced by skin sensitisers.Computational and structural biotechnology journal · 2022Article
- A contemporary review on the important role ofInformatics in medicine unlocked · 2022Review
- How can we accelerate COVID-19 vaccine discovery?Expert opinion on drug discovery · 2021Article
- The COVID-19 vaccine development: A pandemic paradigm.Virus research · 2021Review
- Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review).International journal of oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects.
resultsWe present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.
conclusionsIn silico trials are showing to be powerful weapons in predicting immune responses of potential candidate vaccines. Here, UISS has been extended to be used as an in silico trial platform to speed-up and drive the discovery pipeline of vaccine against SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.